Hiroshi Matsumoto

Gunma University, Maebashi, Gunma Prefecture, Japan

Are you Hiroshi Matsumoto?

Claim your profile

Publications (12)15.8 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Paclitaxel therapy often causes musculoskeletal pain, and some clinical studies have indicated that this pain is due to nerve injury, rather than muscle or joint lesion. We report four clinical cases in which controlled-release oxycodone improved pain intensity in breast cancer patients with severe musculoskeletal pain caused by nab-paclitaxel therapy. In each case, oxycodone was well-tolerated and the symptoms of peripheral neuropathy were quite mild, indicating that oxycodone exhibited a preventive or therapeutic effect on peripheral neuropathy. Therefore, oxycodone may have favorable efficacy and tolerability against cancer therapy-related pain with a neuropathic element in breast cancer patients.
    Gan to kagaku ryoho. Cancer & chemotherapy 08/2013; 40(8):1021-5.
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Various studies have indicated a worldwide increase in the number of immediate breast reconstruction surgeries. However, breast reconstruction should not delay or prevent postoperative cancer therapeutics such as adjuvant chemotherapy and radiotherapy. In response to these developments, our team researched the impact of immediate breast reconstruction on postoperative adjuvant chemotherapy. METHODS: From April 2006 to March 2011, 116 patients at Saitama Cancer Center underwent postoperative adjuvant chemotherapy following mastectomy with or without immediate breast reconstruction. Fifty patients received postoperative adjuvant chemotherapy following mastectomy with immediate breast reconstruction (IBR group), and 66 patients received the same treatment but without immediate breast reconstruction (non-IBR group). The outcomes were studied retrospectively by chart review. Patients' average age, body mass index, postoperative complication rate, and days to adjuvant chemotherapy were calculated. RESULTS: Mean age and body mass index of patients were 47.0 ± 9.0 years, 22.2 ± 3.0 kg/m(2) and 55.5 ± 10.1 years, 23.0 ± 3.6 kg/m(2) in IBR group and non-IBR group, respectively. Postoperative complication rate was 10.0 % in IBR group and 6.1 % in non-IBR group. Days to adjuvant chemotherapy was 61.0 ± 10.5 days in IBR group and 58.0 ± 12.3 days in non-IBR group. CONCLUSIONS: Although complication rate and days to adjuvant chemotherapy were slightly increased in IBR group, the delay was not critical to the initiation of adjuvant chemotherapy in these patient groups.
    Breast Cancer 06/2013; · 1.33 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: It is still controversial whether axillary lymph node (ALN) dissection (ALND) can be omitted after negative sentinel lymph node (SLN) biopsy (SLNB) in breast cancer (BC) patients with clinically positive ALNs at presentation treated with neoadjuvant chemotherapy (NAC). The study aim was to analyze whether SLNB could be useful in these patients. METHODS: In a retrospective study, eligible patients were women with invasive BC with clinically positive ALNs at presentation, treated with NAC then a total or partial mastectomy, with an intraoperative histological examination of SLNs and non-SLNs suspicious for metastasis followed by ALND. Non-SLNs suspicious for metastasis were defined as hard or large nodes located in the same level of the axilla where clinically positive ALNs had been initially identified. The results of SLNB and clinicopathological characteristics were analyzed for correlation with pathological ALN status. RESULTS: In a consecutive series of 105 women with 107 BC cases, 81 (75.7 %) had at least 1 SLN, and the remaining 26 (24.3 %) had at least 1 non-SLN suspicious for metastasis. The intraoperative (or final) histological examination of these nodes revealed that the false-negative (FN) rate and accuracy were 8.2 (or 6.3) % and 95.1 (or 96.3) %, respectively. Estrogen receptor status at presentation, pathological tumor response, lymphovascular invasion after NAC, and NAC regimen were correlated with pathological ALN status. CONCLUSION: The histological examination of SLNs and that of non-SLNs suspicious for metastasis are useful for predicting pathological ALN status in BC patients with clinically positive ALNs at presentation who are treated with NAC.
    International Journal of Clinical Oncology 05/2012; · 1.41 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Sentinel lymph node biopsy (SLNB) is an important treatment option for breast cancer patients, as it can accurately predict axillary status. Our previous study using dye with or without radioisotope showed the accuracy and sensitivity of SLNB to be 97% and 94%, respectively. Based on these results, axillary lymph node dissection (ALND) was eliminated starting in January, 1999 in patients with intraoperatively negative SLNB at our institution. The present study shows the results and outcomes of SLNB as a sole procedure for patients with invasive breast cancer. Three-hundred-fifty-four patients and 358 cases of invasive breast cancer (4 bilateral breast carcinoma) treated with SLNB alone after an intraoperative negative SLNB were studied prospectively from January 1999 to December 2001. The number of the identified SLNs per case ranged from 1 to 8 (mean, 2.5). Of a total of 358 cases, 297 (83%) were treated with hormone therapy and/or chemotherapy, and 281 (78%) were treated with radiotherapy to the conserved breast (50 Gy+/-10 Gy boost), the axilla (50 Gy), or the both sites. After a median follow-up of 21 (range 6-42) months, no patient developed an axillary relapse. Four cases initially recurred in distant organs and one case in the conserved breast. Our results indicate that an intraoperative negative SLNB without further ALND may be a safe procedure when strict SLNB is performed. To better assess the safety, however, may require longer follow-up.
    Breast Cancer 02/2002; 9(4):344-8. · 1.33 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The correlation between ELISA level and immunohistochemical status for thymidine phosphorylase (TP) in invasive breast carcinoma was examined. Specimens were obtained from 84 patients with invasive breast carcinoma and both the ELISA level and immunohistochemical status for TP of breast carcinoma tissue were determined. The results of ELISA for the 84 cases were categorized into quartiles (E-scores 1 to 4) with every category including an equal number of patients. In addition, both the staining intensity of carcinoma cells and relative number of stained stromal cells identified by immunohistochemistry were classified into 4 degrees (I-scores 1 to 4). We also divided the patients into two groups: a negative group (I-scores 1 and 2) and a positive group (I-scores 3 and 4). Furthermore, sums of scores for carcinoma cells and stromal cells (S-scores 2 to 8) were divided into two groups, a low group (S-scores 2 to 5) and a high group (S-scores 6 to 8). The correlation between the ELISA level and immunohistochemical status for TP was evaluated and the means of the ELISA level of each group were compared. Scores of ELISA (E-scores) were significantly positively-correlated with scores for immunohistochemical status (I-scores) of only carcinoma cells (lambda=0.158, p<0.05). The means of TP levels determined by ELISA were significantly higher in the carcinoma cell-positive group (p<0.01) and summed-score high group (p<0.0002). A positive correlation between the results of the ELISA and immunohistochemical status for TP was found only for carcinoma cells and comparison of means of the ELISA level indicated that they reflected total immunohistochemical TP status of carcinoma cells and stromal cells. Immunohistochemical examinations should be performed to clarify the in situ localization of TP in carcinoma tissue and the results obtained from the immunohistochemistry, as well as the ELISA of TP, may be useful in selection of patients for doxifluridine and capecitabine therapy.
    Anticancer research 01/2002; 22(1A):331-8. · 1.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The efficacy of luteining hormone-releasing hormone (LH-RH) analogue, buserelin, combind with tamoxifen (TAM) on 7,12-dimethylbenz(a)anthracene (DMBA)-induced rat mammary tumors was investigated. Low-dose of TAM (L-TAM), 1 mg/kg daily, significantly suppressed the growth of tumors compared with no treatment group. High-dose of TAM (H-TAM), 10 mg/kg daily, suppressed growth considerably, and there was a significant difference in the antitumor effect between the L-TAM group and the H-TAM group. The combined treatment using buserelin and L-TAM significantly suppressed the tumor growth compared with the treatment using each single agent. LH-RH analogue actually reduced serum estradiol (E2) levels and enhanced the antitumor effect brought by a therapeutical dose of TAM. The reduction of serum cholesterol levels as a beneficial effect of TAM was reserved when combined with buserelin. Insulin-like growth factor 1 (IGF-1) expressions in tumors were significantly decreased in the buserelin and L-TAM group. These results support the usefulness of this combination in clinical use.
    Oncology Reports 01/2002; 9(1):145-51. · 2.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: ObjectiveTo assess recurrence of breast cancer following local excision alone for ductal carcinoma in situ. MethodsEighteen patients who received complete resection for noninvasive ductal carcinoma between 1982 and 1997 were investigated in this study. The mean age of the patients was 45 (29-78) years old. The initial presentation was a clinically palpable tumor in 4 patients, nipple discharge in 6, and microcalcification on mammograms in 8. Patients with palpable tumor underwent wide excision with at least a 2-cm free margin. Patients whose mammograms showed microcalcification underwent lumpectomy, and those who showed nipple discharge underwent duct-lobular segmentectomy. Five patients who underwent lymph node dissection up to level I or II had no lymph node metastasis. The mean follow-up period was 86 months. ResultsLocal recurrence in the conserved breast was seen in five (27.8%) of 18 patients. The actuarial five-year event-free survival was 76.2%. The histological type of the recurrent tumor was ductal carcinoma in situ in three patients and invasive carcinoma in two. There was no difference in age at initial operation or histological subtype between patients with and without recurrent disease, but patients presenting with nipple discharge initially had a significantly shorter ipsilateral disease-free interval than those presenting with tumor or microcalcification on mammograms. All patients with local recurrence in the conserved breast were treated with breast-conserving surgery or subcutaneous mastectomy. ConclusionLocal recurrence frequently occurs in patients presenting with nipple discharge treated by ductlobular segmentectomy for noninvasive ductal carcinoma. Either wide excision with a larger free margin or adjuvant radiation therapy following duct-lobular segmentectomy should be considered for these patients.
    Breast Cancer 01/2001; 8(1):52-57. · 1.33 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A rare case of sudden hemorrhage caused by breast cancer is reported. A 71-year-old woman noted bleeding from her left breast. Physical examination of the left breast showed a localized open cavity accompanied by bleeding and coagulation. The patient had no history of breast trauma or anticoagulation therapy. Incisional biopsy followed by histological examination resulted in a diagnosis of granulation tissue with no cancer cells present. Mammography and ultrasonography indicated probable breast cancer. As a result, a second incisional biopsy was performed, which suggested invasive ductal carcinoma without histological skin invasion. A modified radical mastectomy was performed under a diagnosis of stage II breast cancer. Breast cancer with sudden hemorrhage is rare. We review the literature and discuss the cause of this unusual manifestation.
    Breast Cancer 01/2000; 7(2):176-178. · 1.33 Impact Factor
  • The Kitakanto Medical Journal 01/1998; 48(5):359-362.
  • The Kitakanto Medical Journal 01/1998; 48(5):363-366.
  • The Kitakanto Medical Journal 01/1997; 47(6):449-451.
  • European Journal of Cancer 01/1996; 32:58-58. · 5.06 Impact Factor